Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1185

Sort by

Sort Order Select

Journal Articles

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, MS, Nicola Long, Jessica Leonard, MD, Bill H. Chang, MD PhD, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 3950.

https://doi.org/10.1182/blood-2019-131288

Published: 2019

Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 3926.

https://doi.org/10.1182/blood-2019-131930

Published: 2019

Journal Articles

Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype

Bachar Samra, MD, Guillaume Richard-Carpentier, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Veronica A Guerra, MD, Naval G. Daver, MD, Courtney D. DiNardo, MDMSc, Ghayas C. Issa, MD, Prithviraj Bose, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Gautam M. Borthakur, MD, Guillermo Garcia-Manero, MD, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD

Blood (2019) 134 (Supplement_1): 3834.

https://doi.org/10.1182/blood-2019-125330

Published: 2019

Journal Articles

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Courtney D. DiNardo, MDMSc, Rebecca Olin, MDMS, Jo Ishizawa, MD PhD, Hiroyuki Sumi, PhD, Jingdong Xie, PhD, Kazunobu Kato, MD PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3932.

https://doi.org/10.1182/blood-2019-122241

Published: 2019

Journal Articles

Isolation and Characterization of a CD34 + Sub-Clone in B-Cell Lymphoma

Ayad Al-Katib, MD, Ebrahim Abdul Shukkur, PhD, Ali M Gabali, MD PhD, ALI Raufi, MD, Salah Ebrahim, MD, Mustapha Kandouz, PhD

Blood (2019) 134 (Supplement_1): 3970.

https://doi.org/10.1182/blood-2019-130738

Published: 2019

Journal Articles

Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium

Joanna S. Yi, MD, Tiffany Chambers, MPH, Kelly D Getz, Tamara P. Miller, MDMSc, Evanette Burrows, MPH, Marla Daves, MD, Philip J. Lupo, PhD MPH, Michael E. Scheurer, PhD MPH, Richard Aplenc, MD PhD, Karen R. Rabin, MD PhD, Maria Monica J. Gramatges, MD PhD

Blood (2019) 134 (Supplement_1): 3814.

https://doi.org/10.1182/blood-2019-123992

Published: 2019

Journal Articles

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Zhihong Zeng, Natalia Baran, PhDMD, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha Mary Kuruvilla, MSc, Philip Lorenzi, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Courtney D. DiNardo, MDMSc, Joshua Murtie, Danielle Ulanet, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3911.

https://doi.org/10.1182/blood-2019-125469

Published: 2019

Journal Articles

The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)

Blood (2019) 134 (Supplement_1): 3815.

https://doi.org/10.1182/blood-2019-129396

Published: 2019

Journal Articles

Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL)

Luis E Malpica Castillo, MD, Camila Peña, MD, Christine Rojas, MD, Pilar León, MD, Brady E. Beltrán, MD, Denisse A. Castro, MD, Yesenia M. Huerta- Collado, MD, Mimsy Quinones, MD, Sally Rose Paredes, MD, Henry Idrobo, MD, Ivan Perdomo, MD, Virginia Abello, MD, Lorena Fiad, MD, Victoria Otero, MD, Marialejandra Torres Viera, MD, Luis Villela M, Eduardo Sotomayor, MD, Jorge J Castillo, MD, Juan Carlos Ramos, MD BS

Blood (2019) 134 (Supplement_1): 4045.

https://doi.org/10.1182/blood-2019-122976

Published: 2019

Journal Articles

Application of High-Throughput Sequencing in the Diagnosis of Inherited Immune-Thrombocytopenia from Children Chronic/Refractory ITP

Ma Jingyao, MD, Zhenping Chen, PhDMD, Huiqing LIU, Jialu Zhang, Hao GU, Runhui Wu, MD PhD

Blood (2019) 134 (Supplement_1): 86.

https://doi.org/10.1182/blood-2019-126771

Published: 2019

Journal Articles

Patient Harm from Repetitive Blood Draws and Blood Waste in the ICU: A Retrospective Cohort Study

Thomas Bodley, MD, Maverick Chan, B.Arts Sc., Lauren Clarfield, Olga Levi, BSc, MSc, Avery Longmore, Wendy Lin, Drake Yip, Smith Orla, RN PhD, Jan O Friedrich, MDDPhil, Lisa K. Hicks, MD MSc

Blood (2019) 134 (Supplement_1): 57.

https://doi.org/10.1182/blood-2019-127394

Published: 2019

Journal Articles

Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation

Cindy Lynn Hickey, MDFRCPC, Haesook T. Kim, PhD, Sarah Nikiforow, MD PhD, Mahasweta Gooptu, MD, John Koreth, MBBS, DPhil, Jerome Ritz, MD, Vincent T. Ho, MD, Edwin P. Alyea, III, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Corey Cutler, MD MPH, FRCPC, Rizwan Romee, MD PhD

Blood (2019) 134 (Supplement_1): 4486.

https://doi.org/10.1182/blood-2019-121659

Published: 2019

Journal Articles

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Blood (2019) 134 (Supplement_1): 4516.

https://doi.org/10.1182/blood-2019-127325

Published: 2019

Journal Articles

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

Benedetta Rambaldi, MD, Carol Reynolds, PhD, Sharmila Chamling Rai, BSc, Takeru Asano, MD PhD, Yohei Arihara, MD PhD, Mahasweta Gooptu, MD, John Koreth, MBBS, DPhil, Corey Cutler, MD MPH, FRCPC, Sarah Nikiforow, MD PhD, Vincent T. Ho, MD, Edwin P. Alyea, III, MD, Joseph H. Antin, MD, Rizwan Romee, MD PhD, Robert J. Soiffer, MD, Domenico Russo, MD, Jeanette Ampudia, BSc, Cherie Tracy Ng, PhD MPH, Stephen Connelly, PhD MBA, Jerome Ritz, MD

Blood (2019) 134 (Supplement_1): 4517.

https://doi.org/10.1182/blood-2019-125721

Published: 2019

Journal Articles

Association of Obesity on Laboratory Profiles of Individuals with Type 1 Von Willebrand Disease and Low VWF in the Athn Dataset

Beverly Schaefer, MD, Dunlei Cheng, PhD, Peter A. Kouides, MD

Blood (2019) 134 (Supplement_1): 2415.

https://doi.org/10.1182/blood-2019-123781

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Naval G. Daver, MD, Harry P. Erba, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Jiuzhou Wang, PhD, Kara E. Malcolm, RN, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 2601.

https://doi.org/10.1182/blood-2019-128501

Published: 2019

Journal Articles

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Sean M Post, PhD, Huaxian Ma, MS, Vivian Ruvolo, Xiaorui Zhang, BS, Tomoko Yasuhiro, Kohei Tanaka, Ryohei Kozaki, Toshio Yoshizawa, PhD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Marina Y Konopleva, MD PhD, Steven M. Kornblau, MD, Joseph D. Khoury, MD, Michael Andreeff, MD PhD, Peter P. Ruvolo, PhD

Blood (2019) 134 (Supplement_1): 2550.

https://doi.org/10.1182/blood-2019-128626

Published: 2019

Journal Articles

Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2019) 134 (Supplement_1): 2577.

https://doi.org/10.1182/blood-2019-129884

Published: 2019

Journal Articles

Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia

Maher Albitar, MD, Marina Y Konopleva, MD PhD, Ivan De Dios, BS, Jeffrey Justin Estella, BS, MS, Spiraggelos Antzoulatos, Steven M. Kornblau, MD, Antonio Cavazos, Sanam Loghavi, MD, Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MDMSc

Blood (2019) 134 (Supplement_1): 2730.

https://doi.org/10.1182/blood-2019-127383

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Isolation and Characterization of a CD34 + Sub-Clone in B-Cell Lymphoma

Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)

Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL)

Application of High-Throughput Sequencing in the Diagnosis of Inherited Immune-Thrombocytopenia from Children Chronic/Refractory ITP

Patient Harm from Repetitive Blood Draws and Blood Waste in the ICU: A Retrospective Cohort Study

Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

Association of Obesity on Laboratory Profiles of Individuals with Type 1 Von Willebrand Disease and Low VWF in the Athn Dataset

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only